[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mitral-regurgitation-mr\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mitral-regurgitation-mr":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,43,82,107,130,157,184,214],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100641260","use-of-force-feedback-instruments-with-the-da-vinci-surgical-system-model-is5000-for-mitral-valve-repair-100641260",false,"NCT07655505","Use of Force Feedback Instruments With the da Vinci Surgical System, Model IS5000 for Mitral Valve Repair","A Prospective, Multicenter Clinical Investigation of the Use of Force Feedback Instruments With the da Vinci Surgical System, Model IS5000 for Mitral Valve Repair (MVr)","Inclusion Criteria:\n\n1. Age ≥22 years.\n2. Subjects with mitral regurgitation (MR) resulting from primary (degenerative) etiology with normal ventricular function (left ventricular function \\> 40%) provided that annuloplasty or ventricular repair is feasible robotically.\n3. Subjects with moderate-severe (Grade 3) or severe (Grade 4) mitral regurgitation (MR) confirmed by transthoracic echocardiography (TTE) or transesophageal echocardiography (TEE) within 60 days of surgery or evaluation for surgery.\n4. Subjects with low-moderate operative risk (Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) score of \\\u003C4%).\n5. Subjects that are able to provide written informed consent using the study informed consent form prior to the study.\n6. Subjects that are willing to comply with protocol-specified follow-up visits.\n7. Subjects must be candidates for minimally invasive surgery (no contraindications to robotic approach). Based on the study Investigator's clinical judgement, the Subject is deemed suitable to undergo multiport robotic-assisted surgery for mitral valve repair.\n\nExclusion Criteria:\n\nPREOPERATIVE EXCLUSION CRITERIA:\n\n1. Subjects with symptomatic mitral regurgitation determined to be at prohibitive risk for mitral valve surgery.\n2. Subjects with previous mitral valve surgery, transcatheter repair, or annuloplasty.\n3. Subjects with prior cardiac surgery (endoscopic, open, or robotic) or ipsilateral thoracic surgery (open, endoscopic, or robotic).\n4. Subjects with planned emergent procedure (e.g., cardiogenic shock, acute decompensation requiring immediate surgery).\n5. Subjects requiring surgery with multiple stages (i.e., mitral repair cannot be completed in a single procedure).\n6. Subject with planned major concomitant surgery for a different medical condition (e.g., coronary artery bypass, cancer resection unrelated to mitral regurgitation).\n7. Subjects with non-reparable anatomy.\n8. Subjects with severe pulmonary hypertension (systolic Pulmonary Artery Pressure \\>70 mmHg).\n9. Subjects with severe renal insufficiency (estimated Glomerular Filtration Rate \\\u003C30 mL\u002Fmin\u002F1.73m²) or liver failure (Child-Pugh C).\n10. Subjects with active infection.\n11. Subjects with contraindication to anesthesia\u002Fsurgery (e.g., severe frailty, uncorrectable coagulopathy).\n12. Subjects with any past or ongoing condition, or personal circumstance, that in the Investigator's judgment places the Subject at high surgical risk, deems them unsuitable for mitral valve repair, or might interfere with study participation or data collection (e.g., severe chronic obstructive pulmonary disease, uncontrolled diabetes, immunocompromised state, non-compliance).\n13. Subjects with severe aortic\u002Ftricuspid valve disease requiring concurrent open surgery.\n14. Subjects who are pregnant, suspected pregnancy, or breastfeeding.\n15. Subjects currently participating in another investigational drug\u002Fdevice study or participation in a significant-risk investigational device study within the past 6 months.\n16. Subject with inability to complete follow-up (e.g., geographic inaccessibility, dementia).\n17. Subjects who belong to a vulnerable population (e.g., prisoners, cognitively impaired individuals unable to consent).\n\nINTRAOPERATIVE EXCLUSION CRITERIA:\n\n1. Subject with hemodynamic or respiratory instability that precludes the Investigator from performing the Robotic Assisted Surgery (RAS).\n2. Subject in whom inadequate visualization makes a minimally invasive approach not feasible, as determined by the Investigator assessment prior to docking the robot.\n3. Subject with adhesions, scarring, and disease status in the body which, in the opinion of the investigator, limits the ability to perform the minimally invasive procedure.\n4. Subject has any other condition that, in the judgment of the Investigator, might interfere with the collection of complete quality data.","ALL","22 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to test the safety and effectiveness of Force Feedback instruments used during robotic-assisted mitral valve repair with the da Vinci Surgical System, Model IS5000 (dV5).",[26],"Mitral Regurgitation (MR)",[28,29,30],"Mitral Valve Regurgitation","Mitral Valve Disorder","Mitral Regurgitation","NOT_YET_RECRUITING","2026-06-15",{"date":34,"type":35},"2026-06-18","ACTUAL",{"date":37,"type":20},"2026-06",{"date":39,"type":20},"2027-06",{"name":41,"class":42},"Intuitive Surgical","INDUSTRY",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":62,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100608144","delineate-prospective-100608144","NCT07197736","DELINEATE-Prospective","Deep Learning for Echo Analysis, Tracking, and Evaluation Prospective Evaluation (DELINEATE-Prospective)","DELINEATE","Inclusion Criteria:\n\n* Attending cardiologist employed by Columbia University, ColumbiaDoctors, or NewYork Presbyterian Hospital who reads transthoracic echocardiograms in the Columbia echocardiography laboratory\n* Provided informed consent to take part in the questionnaires or pivotal study\n\nExclusion Criteria:\n\n* Physician in training (cardiology fellow or advanced imaging fellow)","18 Years",{"count":53,"type":20},50,"OBSERVATIONAL","Heart disease is the leading cause of death in the United States, and echocardiography (or \"echo\") is the most common way doctors look at the heart. Echo is safe, painless, and can detect major heart problems, including weak heart pumping and valve disease.\n\nValve disease, especially aortic stenosis (narrowing) and mitral regurgitation (leakage), is common in older adults but often goes undiagnosed. While echo is the main tool for finding valve problems, it takes time, requires expert training, and results can vary between readers.\n\nRecent advances in artificial intelligence (AI), especially deep learning (DL), have shown promise in automatically analyzing heart images. However, past research hasn't fully tackled key echo techniques-like color Doppler and spectral Doppler-that are crucial for measuring how blood moves through heart valves. AI tools also face challenges in being used in everyday medical practice because of workflow issues, lack of real-world testing, and concerns about how the algorithms make decisions.\n\nAt Columbia University Irving Medical Center, researchers have built a large database of heart tests over the last six years and developed AI programs to analyze echocardiograms. The current study will test whether providing AI analysis to cardiologists in real time during echo reading can make the process faster and more consistent.",[57,26,58,59,60,61],"Valve Disease, Aortic","Aortic Stenosis","Valvular Heart Disease","Tricuspid Regurgitation (TR)","Aortic Regurgitation",[63,64,65,66,67,68,69],"artificial intelligence","deep learning","valvular heart disease","echocardiography","cardiovascular disease","mitral regurgitation","aortic stenosis","RECRUITING","2026-04-14",{"date":73,"type":35},"2026-04-16",{"date":75,"type":20},"2026-04-15",{"date":77,"type":20},"2028-10-01",{"name":79,"class":80},"Columbia University","OTHER",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":21,"phases":92,"briefSummary":93,"conditions":94,"keywords":95,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":81},"100631480","safety-and-feasibility-study-of-the-mitrafix-transcatheter-mitral-valve-system-100631480","NCT07501234","Safety and Feasibility Study of the MitraFix® Transcatheter Mitral Valve System","A Prospective Clinical Study to Evaluate the Safety and Clinical Feasibility of the MitraFix® Transcatheter Mitral Valve System","MITRA-EFS","Inclusion Criteria:\n\n* Moderate to severe or severe (≥3+) mitral regurgitation.\n* Age ≥ 18 years.\n* Patients at high risk for traditional open-heart surgery, defined as: STS mortality risk for mitral valve replacement ≥ 8%; OR presence of 2 or more frailty indices; OR presence of 2 or more major organ dysfunctions that cannot be improved post-operatively; OR other comorbidities or factors making them unsuitable for surgery.\n* Anatomically suitable for transcatheter MitraFix® system implantation via a transfemoral-transseptal approach as assessed by the investigator; the transfemoral-transseptal access route meets the requirements of the delivery system.\n* Able to understand the study purpose, voluntarily participate, sign the informed consent form, and willing to accept relevant examinations and clinical follow-ups.\n\nExclusion Criteria:\n\n* Severe mitral stenosis.\n* Severe calcification of mitral leaflets and\u002For annulus; anatomical structures of the mitral valve apparatus (e.g., papillary muscles) unsuitable for device implantation.\n* High risk of left ventricular outflow tract obstruction (LVOTO) based on pre-operative CT\u002FTEE planning (estimated neo-LVOT \\\u003C 150 mm²), which cannot be avoided by procedural optimization.\n* Presence of previous implants in the mitral position (surgical bioprosthetic or mechanical valves, surgical annuloplasty rings, etc.).\n* Infective endocarditis or evidence of active infection.\n* Stroke or transient ischemic attack (TIA) within 90 days.\n* Severe untreated coronary artery disease or acute myocardial infarction within 90 days; or percutaneous coronary intervention (PCI)\u002Fcoronary stent implantation within 90 days.\n* Severe pulmonary hypertension (resting PASP \\> 70 mmHg, assessed as irreversible).\n* Severe right ventricular dysfunction: Tricuspid Annular Plane Systolic Excursion (TAPSE) \\\u003C 17 mm.\n* Concomitant tricuspid valve, aortic valve, or severe great vessel disease requiring surgical or interventional treatment.\n* Left ventricular ejection fraction (LVEF) \\\u003C 30%.\n* Extreme frailty preventing tolerance of the procedure, or in a state of shock requiring circulatory support.\n* Implantation of CRT, CRT-D, or implantable cardioverter-defibrillator (ICD) within 30 days.\n* Chronic dialysis or expected need for long-term dialysis; or severe renal impairment (e.g., eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²) unable to undergo perioperative dialysis.\n* Documented coagulopathy or severe hematological disorders (e.g., platelet count \\\u003C 50×10\\^9\u002FL, active bleeding), or history of heparin-induced thrombocytopenia (HIT).\n* Contraindications to anticoagulant\u002Fantiplatelet therapy that cannot be substituted or bridged.\n* Echocardiographic evidence of any intracardiac mass, or thrombus in the left ventricle or left atrium (including left atrial appendage).\n* Contraindications to transesophageal echocardiography (TEE).\n* Severe allergy to iodine contrast media, nitinol, bovine-derived materials, or other device materials that remains intolerable despite premedication.\n* Life expectancy \\\u003C 12 months.\n* Pregnant or breastfeeding women.\n* Unsuitable for the transfemoral-transseptal approach (e.g., femoral vein diameter, calcification, tortuosity, or atrial septum\u002Fleft atrial anatomy not meeting delivery system requirements).\n* Participation in another clinical study of an investigational device or drug within 3 months prior to screening that may interfere with this study.\n* Any other conditions deemed unsuitable for enrollment by the investigator.",{"count":91,"type":20},5,[23],"The goal of this early feasibility clinical trial is to test a new device called the MitraFix® Transcatheter Mitral Valve System. It aims to learn if the device is safe and if it can help adults who have a severe leaky heart valve (mitral regurgitation). This study is for people who are at high risk for traditional open-heart surgery.\n\nThe main questions it aims to answer are:\n\nIs the MitraFix system safe for participants? Can the device be successfully placed in the heart? Does the device help reduce the valve leak and improve daily life?\n\nParticipants will:\n\nReceive the MitraFix valve through a small tube inserted into a vein in the leg.\n\nVisit the clinic for heart tests, walking tests, and health checks for up to one year after the procedure.",[26],[96,97],"MitraFix","Transcatheter Mitral Valve Replacement","2026-03-26",{"date":100,"type":35},"2026-03-30",{"date":102,"type":20},"2026-03-23",{"date":104,"type":20},"2028-10-23",{"name":106,"class":42},"Mitrassist Lifesciences Limited Co., Ltd.",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":114,"targetDuration":116,"studyType":54,"phases":4,"briefSummary":117,"conditions":118,"keywords":119,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":125,"leadSponsor":127,"locationsCount":129},"100624768","mitral-valve-repair-with-the-chord-x-system-a-long-term-evaluation-100624768","NCT07413926","Mitral Valve Repair With the Chord-X System: A Long Term Evaluation","METRIX","Inclusion Criteria:\n\n* Patient provided written Informed Consent\n* Patient underwent mitral valve procedure (defined as mitral valve surgical intervention via endoscopic, mini thoracotomy, or full sternotomy approach, including mitral annuloplasty with a ring, resection of mitral valve leaflets, and replacement of mitral chordae tendineae) using the Chord-X System as clinically indicated (i.e. not off-label) by Principal Investigator at research site\n* Patient's Chord-X System implant occurred no earlier than January 1, 2022\n* Patient is able and willing to participate in follow-up visits for the duration of the study (i.e. through 10 years post-op)\n\nExclusion Criteria:\n\n* Patient was implanted with the Chord-X System off-label\n* Patient was implanted with the Chord-X System prior to January 1, 2022\n* Patient has had previous mitral valve surgery\n* Patient underwent a multi valve repair procedure\n* Patient with an ejection fraction ≤ 50% at baseline\n* Patient underwent concomitant surgical procedures (except for maze procedure, PFO or LAA closure) at time of mitral repair procedure\n* Patient whose mitral valve procedure was performed as part of an emergency surgery (defined as a time period from diagnosis to surgery of ≤ 48 hours)\n* Patient with persistent or permanent atrial fibrillation\n* Patient with active or a history of endocarditis\n* Patient with congenital heart disease",{"count":115,"type":20},110,"10 Years","The goal of this clinical trial is to strengthen the evidence available for the Chord-X System by collecting follow-up data from patients who underwent Chord-X implant and to evaluate the long-term safety and performance data (out to 10 years). Collecting patient health information over time can help to supplement and improve the care of patients in the future.\n\nParticipants will:\n\nAgree to the collection of their past medical history, and the details of their mitral repair surgery with the Chord-X system, including results of the follow-up examinations after implantation Visit the clinic for the routinely scheduled follow-up examination appointments",[26],[68,120],"Chord-X","2026-02-18",{"date":123,"type":35},"2026-02-20",{"date":37,"type":20},{"date":126,"type":20},"2034-06",{"name":128,"class":42},"Artivion Inc.",4,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":136,"enrollmentInfo":137,"targetDuration":139,"studyType":54,"phases":4,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":4},"100612000","research-on-the-development-and-application-of-a-preoperative-assessment-model-for-transcatheter-mitral-valve-edge-to-edge-repair-based-on-visual-foundation-models-100612000","NCT07247890","Research on the Development and Application of a Preoperative Assessment Model for Transcatheter Mitral Valve Edge-to-Edge Repair Based on Visual Foundation Models","Inclusion Criteria:\n\n1. Age: 18-90 years\n2. Patients with moderate to severe or severe mitral regurgitation as indicated by echocardiography\n\nExclusion Criteria:\n\n1. Moderate or severe aortic stenosis or aortic regurgitation, or following aortic valve replacement\n2. Patients with congenital heart disease\n3. Poor image quality: Insufficient cross-sectional coverage or inability to perform effective mitral valve marking","90 Years",{"count":138,"type":20},800,"2 Days","Mitral regurgitation (MR) is the most prevalent valvular heart disease in China. Transcatheter edge-to-edge repair (TEER) is currently the preferred treatment for patients with severe MR who face high surgical risks. However, existing preoperative assessment methods for TEER suffer from numerous limitations, including complex measurement parameters, high technical demands, and significant subjectivity. Vision Mamba, a cutting-edge technology in the visual domain, overcomes the limitations of common computational units in convolutional neural networks and Transformers through bidirectional state space models and positional encoding, demonstrating exceptional performance in visual tasks. To date, no studies have applied Vision Mamba to ultrasound videos for constructing TEER preoperative assessment models. Our team previously established a Transformer-based evaluation model using a small, single-center cohort. This study innovatively introduces a Vision Mamba-based visual foundation model. By integrating multi-faceted, multi-modal ultrasound videos from multiple centers, we develop a one-stop preoperative TEER assessment model for MR patients \\[slice identification → video analysis → multi-modal information fusion → preoperative assessment recommendation (suitable\u002Fchallenging\u002Funsuitable)\\]. This model will optimize surgical patient identification and accurately screen patients with contraindications. Furthermore, the one-stop model is fast and objective, significantly improving clinical efficiency. It holds promise for deployment at primary care levels to optimize healthcare resource allocation.",[26],[143,144,145,146],"Mitral regurgitation (MR)","Transcatheter Mitral Valve Edge-to-Edge Repair","Vision Mamba","Visual Foundation Model","2025-11-18",{"date":149,"type":35},"2025-11-25",{"date":151,"type":20},"2025-12",{"date":153,"type":20},"2027-12",{"name":155,"class":156},"Beijing Hospital","OTHER_GOV",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":167,"conditions":168,"keywords":170,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":81},"100583481","mitral-regurgitation-risk-assessment-and-clinical-modelling-100583481","NCT06876883","MItral Regurgitation Risk Assessment and CLinical modElling","MItral Regurgitation Risk Assessment and CLinical modElling (MIRACLE Study)","MIRACLE","Inclusion Criteria:\n\n* Patients diagnosed with ≥ moderate mitral regurgitation during hospitalization.\n* Aged over 18 yrs.\n\nExclusion Criteria:\n\n* Patients unable to provide written consent.",{"count":166,"type":20},2000,"Mitral regurgitation (MR) is a common valvular heart disease worldwide, and untreated severe MR is associated with an elevated risk of heart failure and mortality. According to causes, MR could be divided into primary or secondary MR. The risk factors of mortality or heart failure hospitalization in different types of MR patients are under intensive investigation.\n\nMItral Regurgitation risk Assessment and CLinical modElling (MIRACLE) study is a prospective cohort study including adult patients diagnosed with ≥ moderate MR during hospitalization. Comprehensive echocardiographic examination was conducted at baseline evaluating valvular heart disease severity, atrial and ventricular systolic\u002Fdiastolic function, pulmonary artery systolic pressure (PASP), etc. We aim to evaluate the prognostic risk factors of patients with MR and construct a prognostic clinical model to guide clinical decision-making.",[169,26],"Mitral Insufficiency",[68,171,172,173,174],"all-cause mortality","clinical modelling","cardiovascular mortality","heart failure hospitalization","2025-08-28",{"date":177,"type":35},"2025-09-05",{"date":179,"type":35},"2016-06-15",{"date":181,"type":20},"2030-06-15",{"name":183,"class":80},"Sun Yat-sen University",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":21,"phases":194,"briefSummary":195,"conditions":196,"keywords":197,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":213},"100598085","quantification-of-mitral-regurgitation-using-4d-mri-flow--comparison-with-2d-mri-flow-and-echocardiography-using-the-evolution-of-left-ventricular-remodeling-as-a-reference-100598085","NCT07066904","Quantification of Mitral Regurgitation Using 4D MRI Flow : Comparison With 2D MRI Flow and Echocardiography Using the Evolution of Left Ventricular Remodeling as a Reference","FLAME","Inclusion Criteria: Subjects\n\n* from 18 to 85 years old\n* having signed a consent form to participate in the study\n* suffering from mild, moderate or severe mitral regurgitation based on an ultrasound graduation\n* able to undergo echocardiography and IRM within 7 days after recruitment and then at 6 months\n\nExclusion Criteria: Subjects\n\n* suffering from aortic regurgitation or stenosis or mitral stenosis associated with more than moderate MR, intracardiac shunting or hypertrophic cardiomyopathy\n* suffering from secondary MR\n* having a contraindication to gadolinium-based contrast agent\n* having a pacemaker, defibrillator or any other contraindication to MRI\n* suffering from renal disease with an eGFR CKD-EPI \\\u003C 30 ml\u002Fmin\n* pregnant or breastfeeding\n* under legal protection\n\nEnrolled subjects:\n\n* with an incomplete or suboptimal ultrasound or MRI examination\n* who have not attended to the 6-month follow-up visit\n* with an intercurrent medical event\n\nwill be excluded.","85 Years",{"count":193,"type":20},160,[23],"The goal of this study is to evaluate whether 4D MRI provides a better assessment of mitral regurgitation quantification and associated ventricular remodeling than standard imaging techniques: echocardiography and 2D MRI, in patients suffuring from mitral regurgitation. 4D MRI demonstrated its superiority to 2D MRI in some other valve diseases but remains not widely used, due to a lack of evidence. The main question our study aims to answer is:\n\n• Is mitral regurgitant volume measured on 4D MRI more strongly related to remodeling progression (after correction of regurgitation or not) than regurgitant volume measured on 2D MRI and echocardiography?\n\nParticipants will undergo 4D MRI, 2D MRI and echocardiography twice at six-month intervals.",[26],[198,199,200,201,202,203],"Mitral regurgitation","4D MRI","4D-flow MRI","cardiovascular magnetic resonance","Ultrafast ultrasound imaging","ultrafast echocardiography","2025-07-04",{"date":206,"type":35},"2025-07-15",{"date":208,"type":20},"2025-10-01",{"date":210,"type":20},"2028-04-30",{"name":212,"class":80},"Assistance Publique - Hôpitaux de Paris",3,{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":222,"enrollmentInfo":223,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":224,"conditions":225,"keywords":226,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":81},"100596461","the-prospective-segeberg-registry-for-mitral-transcatheter-edge-to-edge-repair-100596461","NCT07045753","The Prospective Segeberg Registry for Mitral Transcatheter Edge-to-Edge Repair","A Prospective Follow-up Assessment in Bad Segeberg With Patients With Severe Mitral Regurgitation Undergoing Mitral Edge-to-edge Repair (M-TEER).","SK M-CLIP","Inclusion Criteria:\n\n* Patients with severe MR undergoing M-TEER\n\nExclusion Criteria:\n\n* None","100 Years",{"count":166,"type":20},"A Prospective Follow-up Assessment in Bad Segeberg for Patients with severe MR undergoing M-TEER",[26],[227,228],"M TEER","Mitral Clip","2025-06-22",{"date":231,"type":35},"2025-07-01",{"date":233,"type":35},"2011-01-01",{"date":235,"type":20},"2032-12-31",{"name":237,"class":80},"Segeberger Kliniken GmbH"]